Summit Therapeutics SMMT Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's stock-based comp?
- Summit Therapeutics (SMMT) reported stock-based comp of $72.79M in Q1 2026.
- How has Summit Therapeutics's stock-based comp changed year-over-year?
- Summit Therapeutics's stock-based comp increased by 556.0% year-over-year, from $11.1M to $72.79M.
- What is the long-term trend for Summit Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Summit Therapeutics's stock-based comp has grown at a 175.0% compound annual growth rate (CAGR), from $12.8M to $732.42M.
- What does stock-based comp mean?
- Non-cash costs related to employee stock awards and options.
- How do you interpret stock-based comp?
- High levels indicate significant use of equity for compensation, which may lead to shareholder dilution.
- How does stock-based comp compare across companies?
- Very common in high-growth biopharma and technology sectors to preserve cash.